Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain
Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin
An analyses by bluebird bio probably rules out its gene therapy as the culprit behind a patient in its SCD study developing acute myeloid leukemia • Source: Shutterstock
